ALEXANDRIA, Va., June 12 -- United States Patent no. 12,295,987, issued on May 13, was assigned to Eli Lilly and Co. (Indianapolis).
"Method of using a GIP/GLP1 co-agonist for diabetes" was invented by Jorge Alsina-Fernandez (Indianapolis), Over Cabrera (Carmel, Ind.) and Tamer Coskun (Carmel, Ind.).
According to the abstract* released by the U.S. Patent & Trademark Office: "Provided herein are methods of treating type 2 diabetes (T2D) using a novel dosing regimen of a GIP:GLP-1 Peptide having a GIP:GLP-1 receptor agonist potency ratio that is about 2.5:1 to about 10:1 GIP to GLP-1. Also provided herein are methods of treating T2D using a novel dosing regimen of a GIP:GLP-1 Peptide having a GIP:GLP-1 receptor agonist potency ratio that is...